Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Pl...

by Strojek, Krzysztof, Yoon, Kun-Ho, Hruba, Veronika, Sugg, Jennifer, Langkilde, Anna Maria, Parikh, Shamik
Published 2014

Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data

by Bujac, Sarah, Del Parigi, Angelo, Sugg, Jennifer, Grandy, Susan, Liptrot, Tom, Karpefors, Martin, Chamberlain, Chris, Boothman, Anne-Marie
Published 2014

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled...

by Cefalu, William T., Leiter, Lawrence A., de Bruin, Tjerk W.A., Gause-Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J.
Published 2015